Park Ha Biological Technology Co., Ltd.
BYAH
$1.05
$0.010.96%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.99% | 22.45% | 42.65% | 17.06% | -3.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.99% | 22.45% | 42.65% | 17.06% | -3.14% |
| Cost of Revenue | -27.02% | -37.78% | -45.18% | -40.99% | -37.17% |
| Gross Profit | 8.96% | 29.97% | 57.70% | 26.13% | 1.78% |
| SG&A Expenses | 1,838.73% | 1,910.96% | 2,006.58% | 1,069.58% | 44.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1,579.50% | 1,553.46% | 1,522.65% | 791.67% | 24.21% |
| Operating Income | -3,142.20% | -3,200.80% | -3,278.57% | -1,124.31% | -32.76% |
| Income Before Tax | -3,135.54% | -3,195.12% | -3,274.28% | -1,121.10% | -32.85% |
| Income Tax Expenses | -10.80% | 42.90% | 129.05% | 45.34% | -4.49% |
| Earnings from Continuing Operations | -5,190.85% | -5,075.13% | -4,937.09% | -1,610.36% | -43.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5,190.85% | -5,075.13% | -4,937.09% | -1,610.36% | -43.83% |
| EBIT | -3,142.20% | -3,200.80% | -3,278.57% | -1,124.31% | -32.76% |
| EBITDA | -3,044.56% | -3,096.70% | -3,165.42% | -1,098.40% | -32.00% |
| EPS Basic | -4,692.96% | -4,646.54% | -4,591.15% | -1,499.36% | -43.83% |
| Normalized Basic EPS | -2,839.46% | -2,926.82% | -3,042.86% | -1,043.58% | -32.84% |
| EPS Diluted | -4,693.36% | -4,647.79% | -4,593.39% | -1,499.81% | -43.81% |
| Normalized Diluted EPS | -2,839.46% | -2,926.82% | -3,042.86% | -1,043.58% | -32.84% |
| Average Basic Shares Outstanding | 17.77% | 10.77% | 3.77% | 1.89% | 0.00% |
| Average Diluted Shares Outstanding | 17.77% | 10.77% | 3.77% | 1.89% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |